Smaller sized doses for perioral treatment than for upper facial applications are utilised given that the oral musculature responds more strongly to a similar BTX-A dosing. Just one preparation of botulinum toxin type B (MyoBloc®/NeuroBloc®) exists. Its sole indicator and FDA approval li